Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01306292 · ClinicalTrials.gov registry record · Phase 2
Safety of SonoVue on Pulmonary Hemodynamics
A Phase 2 study, sponsored by Bracco Diagnostics.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT01306292: Completed Phase 2 study, sponsored by Bracco Diagnostics.
NCT01306292 is a Phase 2 study that has completed, run by Bracco Diagnostics. The registered enrollment target is 36 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01306292, a Phase 2 study, has completed, sponsored by Bracco Diagnostics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
This is an intra-subject crossover comparative safety study to evaluate the effect of intravenous (IV) bolus injection of SonoVue on pulmonary hemodynamics.
Primary Outcome
A total of 36 subjects were enrolled in this crossover study: 18 (8 randomized to placebo then SonoVue and 10 randomized to SonoVue then placebo) in the Hypertension Group (baseline mean pulmonary artery pressure (PAP) \>=25.0 mmHg group) and 18 (10 randomized to placebo then SonoVue and 8 randomized to SonoVue then placebo) in the Normal group (baseline mean PAP \<25.0 mmHg group). All subjects in this study were to have systolic PAP recorded within 5 minutes before the first investigational pr
Interventions
- DRUG Placebo
- DRUG SonoVue
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2011-04 |
| Est. Completion | 2011-11 |
| Phase | Phase 2 |
What the finished NCT01306292 record still lists
NCT01306292 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01306292 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01306292 about?
NCT01306292 is a clinical study titled "Safety of SonoVue on Pulmonary Hemodynamics". This is an intra-subject crossover comparative safety study to evaluate the effect of intravenous (IV) bolus injection of SonoVue on pulmonary hemodynamics.
What is the current status of trial NCT01306292?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2011-04. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01306292?
The interventions under investigation include: Placebo (DRUG), SonoVue (DRUG).
Who is sponsoring clinical trial NCT01306292?
This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01306292's enrollment target sits among peer trials
36 1496th of 2000 higher than 477 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia